Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836

NCT06582277 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
117
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Osivax

Collaborators